Drug interactions
Armodafinil + Lurbinectedin
Severity: Moderate
Armodafinil and Lurbinectedin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Armodafinil is a weak-to-moderate CYP3A4 inducer and may lower lurbinectedin exposure. Lower exposure could reduce antitumor efficacy. The labeling advises avoiding CYP3A inducers, mainly the strong ones.
What this interaction means in plain words
Armodafinil and Lurbinectedin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Armodafinil belongs to Central Nervous System; Lurbinectedin belongs to Oncology.
Why it happens
Induction of CYP3A4 by armodafinil increases the metabolism of lurbinectedin, a CYP3A4 substrate.
What to do
Prefer a non-inducing alternative for wakefulness during lurbinectedin therapy. If the combination is unavoidable, monitor for reduced oncologic response.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Armodafinil and Lurbinectedin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Armodafinil
Other interactions of Lurbinectedin
Frequently asked questions
Can I take Armodafinil with Lurbinectedin?
MediHelp rates the interaction as moderate. Armodafinil and Lurbinectedin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Armodafinil is a weak-to-moderate CYP3A4 inducer and may lower lurbinectedin exposure. Lower exposure could reduce antitumor efficacy. The labeling advises avoiding CYP3A inducers, mainly the strong ones.
How serious is the interaction between Armodafinil and Lurbinectedin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer a non-inducing alternative for wakefulness during lurbinectedin therapy. If the combination is unavoidable, monitor for reduced oncologic response.
What other medicines interact with Armodafinil?
MediHelp also lists interactions of Armodafinil with, for example, Avapritinib, Elacestrant, Elbasvir / grazoprevir. The full list is on the Armodafinil page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
